Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study
Main finding · PrediabetesResult — go to the resultHazard ratio 2.03 CI 1.51–2.72Authors' conclusion
In this large-scale cohort study, teprotumumab treatment was associated with an increased risk of dysglycemia. Although this risk was observed across several glycemic outcomes, the absolute risk increase was modest. These findings support routine glucose monitoring and proactive glycemic management, while emphasizing the importance of individualized risk-benefit assessment when considering teprotumumab therapy in patients with TED.
Study context
- Population
- Patients with thyroid eye disease (TED), TriNetX Global Collaborative Network (>165 health care organizations worldwide)matched cohort
- Participants
- 792 vs 792
- Exposure
- Teprotumumab vs no teprotumumab in TED
- Teprotumumabn = 792
- Controlsn = 792reference
- Outcome
- Incident prediabetes, diabetes, hyperglycemia (random blood glucose ≥200 mg/dL), and initiation of antidiabetes medications
- Follow-up
- 6 months to 5 years
Methodological detailsmultinational, propensity score matching (PSM), TriNetX Global Collaborative Network
- Multinational
- Propensity score matching (PSM)
- TriNetX Global Collaborative Network
Main finding
Prediabetes · up to 5 years
Hazard ratio
2.03
CI 1.51–2.72
By group
Teprotumumabvs Controls
HR 2.03 (CI 1.51–2.72)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| Incident diabetes · up to 5 years | 2.23 (1.46–3.43) | |
| Addition of antidiabetes medications · up to 5 years | 1.68 (1.27–2.22) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study. Thyroid. Published 9 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →